MT-1621
Drug
Zogenix Inc.
Total Payments
$44,000
Transactions
5
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $44,000 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $44,000 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 (Continuation) | Zogenix Inc. | $44,000 | 0 |
Top Doctors Receiving Payments for MT-1621
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Richard Kim | — | Redwood City, CA | $44,000 | 5 |
Ad
Manufacturing Companies
- Zogenix Inc. $44,000
Product Information
- Type Drug
- Total Payments $44,000
- Total Doctors 0
- Transactions 5
About MT-1621
MT-1621 is a drug associated with $44,000 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Zogenix Inc..
Payment data is available from 2020 to 2020. In 2020, $44,000 was paid across 5 transactions to 0 doctors.
The most common payment nature for MT-1621 is "Unspecified" ($44,000, 100.0% of total).
MT-1621 is associated with 1 research study, including "An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 (Continuation)" ($44,000).